Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...